Cision PR Newswire

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, reflects on a landmark year of innovation and achievement. Despite global market uncertainties, the Company remained at the forefront of medical technology, driving advancements in MWA solutions and expanding its presence in the global healthcare sector.

Nasdaq Listing

On October 2, 2024 (U.S. Eastern Time), Baird Medical successfully listed on the Nasdaq Stock Market, marking a significant milestone in its international growth strategy. This listing reinforces the Company's commitment to innovation, global market expansion, and enhancing shareholder value as it continues to pioneer cutting-edge medical solutions.

Patents

In 2024, Baird Medical further expanded its intellectual property portfolio, securing patents that enhance MWA technology and production efficiency:

1. Invention Patent: Semi-rigid Penetrating  Microwave Ablation Antenna, Transmission Line Structure, and Assembly Method
2. Invention Patent: Assembly Method and Transmission Line Structure for a Semi-flexible Microwave Ablation Antenna
3. Utility Model Patent: Automated Drying Device

These patents center on the design and assembly of microwave ablation antennas, as well as the application of automated drying technology—advancements that showcase the Company's leadership in refining MWA solutions.

Class III Medical Device Production License in China

The Company obtained a Class III Medical Device Production License in China in 2024, enabling high-volume production and broader market adoption of its advanced medical devices.

Industry Recognition & Awards

Baird Medical's relentless focus on R&D and commercialization has been recognized through several prestigious industry honors, reinforcing its impact in oncology treatment and medical innovation.

• 2024 Suzhou Engineering Technology Research Center (Suzhou Tumor Microwave Ablation Treatment System Engineering Technology Research Center)
• Jiangsu Province High-Tech Enterprise
• "Most Investment Value Award" at the 10th China Medical Industry Innovation Competition

Nanjing Great Wall: A Subsidiary Driving Medical Innovation

As a subsidiary of Baird Medical Investment Holdings Ltd., Nanjing Great Wall further cemented its position in minimally invasive treatments with four newly granted patents, focused on vascular thermal coagulation, RF ablation catheter optimization, and advanced MWA needle designs:

Patents

1. Invention Patents
• Semi-rigid Endovascular Microwave Thermal Coagulation Antenna
• Adjustable-Bending Radiofrequency Ablation Catheter and Its Operating Method
2. Utility Model Patents
• Microwave Ablation Needle with Drilling Functions
• Microwave Ablation Probe

Class III Medical Device Registration Certificate in China

Nanjing Great Wall secured a Class III Medical Device Registration Certificate in China (No. 20243010517) for its Disposable Microwave Ablation Needle (Rare Earth Ceramic Needle for Thyroid)—further validating its safety and clinical effectiveness.

ISO 13485 Certification

To enhance international market accessibility, Nanjing Great Wall successfully obtained ISO 13485 certification, demonstrating its commitment to stringent global quality management standards for medical devices.

For Baird Medical and its subsidiaries, 2024 was a year defined by innovation, recognition, and growth. Building on these achievements, Baird Medical is poised to accelerate global expansion, deepen its investment in next-generation ablation technology, and strengthen collaborations with leading healthcare institutions. As the Company continues to push the boundaries of minimally invasive treatment, its focus remains on improving patient outcomes worldwide.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-celebrates-2024-breakthroughs-and-accolades-forging-a-new-era-in-minimally-invasive-mwa-technology-302360560.html

SOURCE BDMD